Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Tee

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Molecular and Cellular Biology|December 16, 2003
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4EDiane C Fingar, Celeste J Richardson, Andrew R Tee, et al.
The Journal of Biological Chemistry|March 18, 2005
The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stressesEwan M Smith, Stephen G Finn, Andrew R Tee, et al.
Autophagy|April 5, 2011
ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate bindingElaine A Dunlop, David K Hunt, Hugo A Acosta-Jaquez, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2002
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signalingAndrew R Tee, Diane C Fingar, Brendan D Manning, et al.
Cellular Signalling|July 19, 2011
cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activityJianling Xie, Godwin A Ponuwei, Claire E Moore, et al.
American Journal of Physiology. Endocrinology and Metabolism|July 23, 2009
Tertiary active transport of amino acids reconstituted by coexpression of System A and L transporters in Xenopus oocytesFiona E Baird, Kevin J Bett, Catherine MacLean, et al.
Journal of Extracellular Vesicles|June 20, 2023
Tuberous Sclerosis Complex cell-derived EVs have an altered protein cargo capable of regulating their microenvironment and have potential as disease biomarkersMuireann Ní Bhaoighill, Juan M Falcón-Pérez, Félix Royo, et al.
Cancers|October 13, 2018
Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine TreatmentHenry D McCann, Charlotte E Johnson, Rachel J Errington, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2013
Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1Durga N Tripathi, Rajdeep Chowdhury, Laura J Trudel, et al.
The Journal of Biological Chemistry|December 22, 2009
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of actionGhada A Soliman, Hugo A Acosta-Jaquez, Elaine A Dunlop, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Molecular and Cellular Biology|December 16, 2003
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4EDiane C Fingar, Celeste J Richardson, Andrew R Tee, et al.
The Journal of Biological Chemistry|March 18, 2005
The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stressesEwan M Smith, Stephen G Finn, Andrew R Tee, et al.
Autophagy|April 5, 2011
ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate bindingElaine A Dunlop, David K Hunt, Hugo A Acosta-Jaquez, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2002
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signalingAndrew R Tee, Diane C Fingar, Brendan D Manning, et al.
Cellular Signalling|July 19, 2011
cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activityJianling Xie, Godwin A Ponuwei, Claire E Moore, et al.
American Journal of Physiology. Endocrinology and Metabolism|July 23, 2009
Tertiary active transport of amino acids reconstituted by coexpression of System A and L transporters in Xenopus oocytesFiona E Baird, Kevin J Bett, Catherine MacLean, et al.
Journal of Extracellular Vesicles|June 20, 2023
Tuberous Sclerosis Complex cell-derived EVs have an altered protein cargo capable of regulating their microenvironment and have potential as disease biomarkersMuireann Ní Bhaoighill, Juan M Falcón-Pérez, Félix Royo, et al.
Cancers|October 13, 2018
Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine TreatmentHenry D McCann, Charlotte E Johnson, Rachel J Errington, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2013
Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1Durga N Tripathi, Rajdeep Chowdhury, Laura J Trudel, et al.
The Journal of Biological Chemistry|December 22, 2009
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of actionGhada A Soliman, Hugo A Acosta-Jaquez, Elaine A Dunlop, et al.
Pageof 7